This biotechnology company, dedicated to revolutionizing drug discovery with artificial intelligence, has yet to prove its worth. Recursion Pharmaceuticals (RXRX) has a relatively small market capitalization, and its stock price experienced a significant decline last year. Could 2026 be the year it turns things around?
Recursion Pharmaceuticals uses an AI operating system to screen clinical compounds and advance the most promising candidates into clinical trials. The company claims its approach could improve R&D success rates while reducing the time and cost of preclinical studies. If this vision materializes, it could bring transformative changes to the pharmaceutical industry.
However, do investors have sufficient reasons to believe Recursion can achieve its goals? So far, the evidence is limited. The company’s most advanced drug candidates are still in mid-stage studies, and multiple data readouts are expected over the next year or so. For example, clinical trial results for the potential anti-cancer drug REC-1245 are anticipated in the first half of the year, while data from the REC-102 study targeting hypophosphatasia—a disorder causing brittle bones and teeth—may be released in the second half.
It should be noted, however, that these are early-stage (Phase I) clinical data, focusing primarily on safety and tolerability rather than efficacy, which may limit their potential to drive significant stock price momentum.
Even if Recursion Pharmaceuticals achieves clinical progress this year, the impact may be modest. At the same time, the company is facing increasingly fierce competition, particularly from pharmaceutical giant Eli Lilly. Lilly is building an industry-leading supercomputing system to strengthen its AI-powered drug discovery platform. One of Recursion’s long-term goals is to license its AI models to other pharmaceutical companies once its approach is validated. However, if competitors develop equally capable platforms, this plan will be harder to realize.
Eli Lilly’s resources—including funding and clinical data—far surpass those of the smaller Recursion, giving it a significant advantage in training AI models. For now, Recursion has no approved products and has not yet progressed to Phase III clinical trials, making any definitive judgments premature.
For Recursion Pharmaceuticals, proving its value may still require considerable time. Amid increasing competition and an unproven product pipeline, the path to revival for this AI-driven biotech company remains uncertain.
